Wednesday, July 8, 2026

pharma · Hypertriglyceridemia · Asthma · GRCE

Grace Therapeutics

Grace Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA HQ
18 Employees
Public company Type
GRCE · NYSE Ticker
Company details
Status
Public
HQ
3009, boul. de la Concorde E., Suite 102, Laval, Québec H7E 2B5, CA
Employees
18
Programs
29
Drugs
37
Patents
34
Intelligence · Clinical Programs

Grace Therapeutics projects

5 ClinicalTrials.gov programs sponsored by Grace Therapeutics.

Grace Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CaPre (TM)

    Grace Therapeutics

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial
  2. Clonidine

    Grace Therapeutics

    Pregnancy Related

    phase 2 small molecule completed

    1 trial
  3. Eat Well Live Well Nutrition Program

    Grace Therapeutics

    Diabetes or Diabetes Prevention

    phase 2 other completed

    1 trial
  4. Ketamine

    Grace Therapeutics

    Obstetric Pain

    phase 2 small molecule completed

    1 trial
  5. Lipid Lowering Medication

    Grace Therapeutics

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Grace Therapeutics have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.